Hui Liu

Hui is a seasoned biopharma executive with 25 years of experience in business development, finance, and strategy. He is currently the Executive Vice President, Chief Business Officer and Head of US at Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company engaged in developing multispecific antibody therapeutics. Prior to Merus, Hui was the Global Head of Business Development & Licensing at Novartis Oncology. Prior to this, he served as Global Head of Business Development and Licensing for Novartis Vaccines & Diagnostics. Hui began his pharma career in business development at Pfizer where he held roles of increasing responsibility. Prior to Pfizer, he worked in investment banking at Citigroup and Goldman Sachs.

Hui earned a B.S. in biology from Peking University in Beijing, China and both an M.B.A. in finance and Ph.D. in molecular biology from the University of Michigan.